BACKGROUND: Clinical efficacy of thrombolytic drugs is limited by lack of specific delivery and requires large therapeutic doses which increase toxicity. Encapsulating these drugs in temperature-sensitive liposomes and applying hyperthermia to deliver thrombolytic agents locally to thrombus might theoretically favourably alter the therapeutic window. The objectives of this study were to formulate liposomes encapsulating thrombolytics and assess thrombolytic activity following hyperthermia. METHODS: Three liposome formulations were investigated: temperature-sensitive liposome (TSL, DPPC:DSPE-PEG2000 (mol% 95:5)), low temperature-sensitive liposome (LTSL, DPPC:MSPC:DSPE-PEG2000 (mol% 85.3:9.7:5)), and traditional temperature-sensitive liposome (TTSL, DPPC:HSPC:Chol:DSPE-PEG2000 (mol% 55:25:15:5)). To characterise temperature-dependent release of high molecular weight cargo from each formulation, fluorescein-conjugated dextrans (70 kDa) were loaded and release was quantified via spectrophotometry. Staphylokinase (SAK), urokinase, and tissue-type plasminogen activator were also loaded individually into each liposome formulation. Leakage at 37 °C and release at 38-44 °C were quantified via chromogenic enzymatic activity assay. Clot lysis was evaluated by measuring mass of blood clots before and after thrombolytic liposome treatment. RESULTS: The LTSL formulation had optimal release characteristics with maximum release at 41.3 °C. Release of dextrans from LTSLs was observed to be 11.5 ± 1.5%, 79.7 ± 1.6%, and 93.6 ± 3.7% after 15 min in plasma at 37°, 39°, and 41.3 °C, respectively. The SAK LTSL had the highest release/leakage ratio and demonstrated greater clot lysis. CONCLUSIONS: The SAK LTSL achieves significant clot lysis in vitro. When combined with local hyperthermia, the SAK LTSL potentially produces sufficient thrombolysis while minimising systemic side effects.
BACKGROUND: Clinical efficacy of thrombolytic drugs is limited by lack of specific delivery and requires large therapeutic doses which increase toxicity. Encapsulating these drugs in temperature-sensitive liposomes and applying hyperthermia to deliver thrombolytic agents locally to thrombus might theoretically favourably alter the therapeutic window. The objectives of this study were to formulate liposomes encapsulating thrombolytics and assess thrombolytic activity following hyperthermia. METHODS: Three liposome formulations were investigated: temperature-sensitive liposome (TSL, DPPC:DSPE-PEG2000 (mol% 95:5)), low temperature-sensitive liposome (LTSL, DPPC:MSPC:DSPE-PEG2000 (mol% 85.3:9.7:5)), and traditional temperature-sensitive liposome (TTSL, DPPC:HSPC:Chol:DSPE-PEG2000 (mol% 55:25:15:5)). To characterise temperature-dependent release of high molecular weight cargo from each formulation, fluorescein-conjugated dextrans (70 kDa) were loaded and release was quantified via spectrophotometry. Staphylokinase (SAK), urokinase, and tissue-type plasminogen activator were also loaded individually into each liposome formulation. Leakage at 37 °C and release at 38-44 °C were quantified via chromogenic enzymatic activity assay. Clot lysis was evaluated by measuring mass of blood clots before and after thrombolytic liposome treatment. RESULTS: The LTSL formulation had optimal release characteristics with maximum release at 41.3 °C. Release of dextrans from LTSLs was observed to be 11.5 ± 1.5%, 79.7 ± 1.6%, and 93.6 ± 3.7% after 15 min in plasma at 37°, 39°, and 41.3 °C, respectively. The SAK LTSL had the highest release/leakage ratio and demonstrated greater clot lysis. CONCLUSIONS: The SAK LTSL achieves significant clot lysis in vitro. When combined with local hyperthermia, the SAK LTSL potentially produces sufficient thrombolysis while minimising systemic side effects.
Entities:
Keywords:
Staphylokinase; temperature sensitive liposomes; thrombolysis; tissue plasminogen activator
Authors: George J Shaw; Jason M Meunier; Shao-Ling Huang; Christopher J Lindsell; David D McPherson; Christy K Holland Journal: Thromb Res Date: 2009-02-13 Impact factor: 3.944
Authors: Michael J Stone; Victor Frenkel; Sergio Dromi; Peter Thomas; Ryan P Lewis; King C P Li; McDonald Horne; Bradford J Wood Journal: Thromb Res Date: 2007-05-04 Impact factor: 3.944
Authors: Lars H Lindner; Martin E Eichhorn; Hansjoerg Eibl; Nicole Teichert; Marcus Schmitt-Sody; Rolf D Issels; Marc Dellian Journal: Clin Cancer Res Date: 2004-03-15 Impact factor: 12.531
Authors: Soodabeh Hassanpour; Han-Jun Kim; Arezoo Saadati; Peyton Tebon; Chengbin Xue; Floor W van den Dolder; Jai Thakor; Behzad Baradaran; Jafar Mosafer; Amir Baghbanzadeh; Natan Roberto de Barros; Mahmoud Hashemzaei; Kang Ju Lee; Junmin Lee; Shiming Zhang; Wujin Sun; Hyun-Jong Cho; Samad Ahadian; Nureddin Ashammakhi; Mehmet R Dokmeci; Ahad Mokhtarzadeh; Ali Khademhosseini Journal: Small Date: 2020-08-12 Impact factor: 13.281
Authors: Anna Tanka-Salamon; Attila Bóta; András Wacha; Judith Mihály; Miklós Lovas; Krasimir Kolev Journal: Biomed Res Int Date: 2017-07-03 Impact factor: 3.411
Authors: Amy Lee Bredlau; Anjan Motamarry; Chao Chen; M A McCrackin; Kris Helke; Kent E Armeson; Katrina Bynum; Ann-Marie Broome; Dieter Haemmerich Journal: Drug Deliv Date: 2018-11 Impact factor: 6.419
Authors: Dmitri Nikitin; Seungbum Choi; Jan Mican; Martin Toul; Wi-Sun Ryu; Jiri Damborsky; Robert Mikulik; Dong-Eog Kim Journal: J Stroke Date: 2021-01-31 Impact factor: 6.967
Authors: Maria B C de Matos; Roel Deckers; Benjamin van Elburg; Guillaume Lajoinie; Bárbara S de Miranda; Michel Versluis; Raymond Schiffelers; Robbert J Kok Journal: Front Pharmacol Date: 2019-12-05 Impact factor: 5.810